PSC
NRIX icon

Patient Square Capital’s Nurix Therapeutics NRIX Stock Holding History

Patient Square Capital’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-437,237
Closed -$4.04M – 32
2025
Q3 		$4.04M Buy
437,237
+24,941
+6% +$259K 1.08% 19
2025
Q2 		$4.7M Sell
412,296
-35,000
-8% -$378K 1.69% 12
2025
Q1 		$5.31M Buy
447,296
+1,000
+0.2% +$16.7K 2.2% 7
2024
Q4 		$8.41M Buy
446,296
+120,507
+37% +$2.76M 3.14% 6
2024
Q3 		$7.32M Buy
+325,789
New +$7.38M 2.72% 6

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Patient Square Capital's NRIX Position: Q4 2025 in Review

Patient Square Capital sold out of Nurix Therapeutics (NRIX) in Q4 2025, closing a stake of 437,237 shares — an estimated $4.04M sold.

Patient Square Capital first reported a position in NRIX in Q3 2024 and held it in 5 quarters. The position peaked at $8.41M in Q4 2024. 182 funds tracked by Wall St. Rank hold NRIX as of Q4 2025.

  • Patient Square Capital reported no remaining Nurix Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Patient Square Capital sold 437,237 Nurix Therapeutics shares in Q4 2025, an estimated $4.04M.
  • Patient Square Capital first reported a position in Nurix Therapeutics in Q3 2024 and held it in 5 quarters.
  • Patient Square Capital's Nurix Therapeutics position peaked at $8.41M in Q4 2024.
  • 182 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2025.

Based on Patient Square Capital's 13F filing for Q4 2025, filed 12 Feb 2026.